Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti T-lymphocyte globulin - Neovii Biotech

Drug Profile

Anti T-lymphocyte globulin - Neovii Biotech

Alternative Names: Anti-T-lymphocyte immune globulin; Antithymocyte globulin - Fresenius; Antithymocyte immunoglobulin (rabbit) - Neovii Biotech; ATG S Fresenius; ATG-Fresenius-S; ENZN-2053; EZ-2053; Grafalon; US-ATG-F

Latest Information Update: 27 Jan 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Fresenius Biotech
  • Developer Neovii Biotech
  • Class Polyclonal antibodies
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease
  • New Molecular Entity No

Highest Development Phases

  • Marketed Graft-versus-host disease; Renal transplant rejection; Transplant rejection
  • Discontinued Lung transplant rejection

Most Recent Events

  • 11 Dec 2021 Interim efficacy data from phase II MDS-ALLO-Risk trial in Graft versus host disease presented at the 63rd American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2021)
  • 19 Feb 2021 Phase-III development is ongoing in the US (Neovii Biotech pipeline, February 2021 )
  • 19 Feb 2021 Discontinued - Phase-III for Graft-versus-host disease (Prevention) in Australia (IV) (Neovii Biotech pipeline, February 2021).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top